Mycobacteria as pathogens of respiratory infection.
As the result of a formidable effort, the recent TB epidemic in the United States has abated; however, major questions remain as the risk of TB diminishes. Will we maintain an adequate public health effort not only to prevent another resurgence of TB but also to renew our pursuit of TB elimination? Do we have the will to extend the fight against TB worldwide as the TB threat in the United States declines? What is the best way to incorporate new diagnostic technology into routine practice? What are the best strategies for preventing and treating TB in AIDS patients? From the standpoint of NTM lung diseases, the major challenges are to educate clinicians about the variety and clinical presentation of NTM lung pathogens in order to recognize NTM lung disease as early as possible and to maximize treatment options. Hopefully, we can also improve upon the recent unprecedented progress in treatment regimens for NTM diseases of all types.
Center for Pulmonary Infectious Disease Control, University of Texas Health Center, Tyler, USA.
D E
DE
Griffith
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001500:BCG Vaccine / Q000627:therapeutic use; D017291:Clarithromycin / Q000494:pharmacology; D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D009161:Mycobacterium / Q000187:drug effects / Q000302:isolation & purification*; D009164:Mycobacterium Infections / Q000150:complications / Q000382:microbiology*; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy; D015269:Mycobacterium avium Complex / Q000187:drug effects / Q000302:isolation & purification; D015270:Mycobacterium avium-intracellulare Infection / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D019909:Mycobacterium kansasii / Q000302:isolation & purification; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D011480:Protease Inhibitors / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D001500:BCG Vaccine; D011480:Protease Inhibitors; D017291:Clarithromycin